Immunodominance across HLA Polymorphism: Implications for cancer immunotherapy

Journal of Immunotherapy

Volumn 21, Issue 1, 1998, Pages 1-16

  Kim, Christina J ^a   Parkinson, David R ^b   Marincola, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CTL; HLA; Immunodominance; Polymorphism

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 2; INTERLEUKIN 2; MELANOMA ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; IMMUNOGENICITY; IMMUNOMODULATION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; MELANOMA; NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 0031983670     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199801000-00001     Document Type: Article

References (129)

1. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
2. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments]. J Exp Med 1994;180:35-42.
3. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
4. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
5. van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. EurJ Immunol 1994;24:3038-43.
6. Kast WM, Roux L, Curren J, et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci USA 1991;88:2283-7.
7. Vitiello A, Ishioka G, Grey HM, et al. Development of lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;95:341-9.
8. Noguchi Y, Richards EC, Chen YT, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 1995;92:2219-23.
9. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
10. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
11. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gplOO by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-9.
12. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA. Differential anti-MART-l/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother 1996;19:266-77.
13. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-l/Melan A. Cancer J Sci Am 1997;3:37-44.
14. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57.
15. Stevens El, lacknin L, Robbins PF, et al. Generation of tumorspecific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines: fine specificity and MART-1 melanoma antigen recognition. J Immunol 1995;154:762-71.
16. Castelli C, Storkus WJ, Maeurer MI, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995;181:363-8.
17. van Elsas A, van der Burg SH, van der Minne CE, Borghi M, Melief CL, Schrier PI. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/ MART-1 self antigen. Eur J Immunol 1996;26:1683-9.
18. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993;11:729-66.
19. Niedermann G, Butz S, Ihlenfeldt HG, et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 1995;2:289-99.
20. van der Burg SH, Visseren MI, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class 1 molecules depends on the MHC-peptide complex stability. J Immunol 1996;156:3308-14.
21. Bjorkman PJ, Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 1990;59:253-88.
22. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-12.
23. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329:512-8.
24. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gplOO by tumorinfiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
25. Topalian SL. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol 1994;6:741-5.
26. Trowsdale J, Ragoussis J, Campbell RD. Map of the human MHC. Immunol Today 1991;12:443-6.
27. Zemmour J, Parham P. Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C. J Exp Med 1992;176:937-50.
28. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
29. Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. Adv Cancer Res 1995;67:155-95.
30. Zemmour J, Parham P. HLA class I nucleotide sequences, 1992. Immunobiology 1993;187:70-101.
31. Player MA, Barracchini KC, Simonis TB, et al. Differences in frequency distribution of HLA-A2 sub-types between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination protocols. J Immunother 1996;19:357-63.
32. Rivoltini L, Loftus DJ, Barracchin K, et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and gplOO by HLA-A2 subtypes: implications for peptide-based immunotherapy. J Immunol 1996;156:3882-91.
33. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1995. Hum Immunol 1995;43:149-64.
34. Barber LD, Parham P. Peptide binding to major histocompatibility complex molecules. In: Palade GE, Alberts BM, Spudich JA, eds. Annual review of cell biology. Palo Alto: Annual Reviews Inc., 1993:163-206.
35. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-6.
36. Falk K, Rotzschke O, Rammensee HG. Cellular peptide composition governed by major histocompatibility complex class I molecules [see comments]. Nature 1990;348:248-51.
37. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2 [published erratum appears in Cell 1994;76:following 410], Cell 1993;75:693-708.
38. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-37.
39. Parker KC, Shields M, DiBrino M, Brooks A, Coligan JE. Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Immunol Res 1995;14:34-57.
40. Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry [see comments]. Science 1992;255:1261-3.
41. Sidney J, Grey HM, Southwood S, et al. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol 1996;45:79-93.
42. Loftus DJ, Kubo RT, Sakaguchi K, Celis E, Sette A, Appella E. Analysis of MHC-specific peptide motifs: applications in immunotherapy. Adv Exp Med Biol 1995;383:201-10.
43. Peruzzi M, Parker KC, Long EO, Malnati MS. Peptide sequence requirements for the recognition of HLA-B*2705 by specific natural killer cells. J Immunol 1996;157:3350-6.
44. DiBrino M, Parker KC, Margulies DH, et al. Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population. Biochemistry 1995;34:10130-8.
45. DiBrino M, Parker KC, Margulies DH, et al. The HLA-B 14 peptide binding site can accommodate peptides with different combinations of anchor residues. J Biol Chem 1994;269:32426-34.
46. DiBrino M, Parker KC, Shiloach J, et al. Endogenous peptides with distinct amino acid anchor residue motifs bind to HLA-A1 and HLA-B8. J Immunol 1994;152:620-31.
47. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
48. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153:5586-92.
49. Chen Y, Sidney J, Southwood S, et al. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J Immunol 1994;152:2874-81.
50. Eggers M, Boes-Fabian B, Ruppert T, Kloetzel PM, Koszinowski UH. The cleavage preference of the proteasome governs the yield of antigenic peptides. J Exp Med 1995;182:1865-70.
51. Spies T, Bresnahan M, Bahram S, et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway [see comments]. Nature 1990;348:744-7.
52. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A. Sequences encoded in the class II region of the MHC related to the ‘ABC’ superfamily of transporters [see comments]. Nature 1990;348:741-4.
53. Androlewicz MJ, Cresswell P. How selective is the transporter associated with antigen processing? Immunity 1996;5:1-5.
54. Schild H, Rotzschke O, Kalbacher H, Rammensee HG. Limit of T cell tolerance to self proteins by peptide presentation. Science 1990;247:1587-89.
55. Sheil JM, Shepherd SE, Klimo GF, Paterson Y. Identification of an autologous insulin B chain peptide as a target antigen for H-2Kb-restricted cytotoxic T lymphocytes. J Exp Med 1992;175:545-52.
56. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
57. Houbiers JG, Nijman HW, van der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;23:2072-7.
58. Oukka M, Riche N, Kosmatopoulos K. A nonimmunodominant nucleoprotein-derived peptide is presented by influenza A virus-infected H-2b cells. J Immunol 1994;152:4843-51.
59. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
60. Kast WM, Brandt RM, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994;152:3904-12.
61. Sadovnikova E, Zhu X, Collins SM, et al. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. Int Immunol 1994;6:289-96.
62. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-9.
63. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-64.
64. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma associated antigens MART-1 and gplOO in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996;19:192-205.
65. Chen Y, Stockert E, Tsang S, Coplan KE, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995;92:8125-9.
66. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 1994;152:2393-400.
67. Christinck ER, Luscher MA, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 1991;352:67-70.
68. Carbone FR, Moore MW, Sheil JM, Bevan MJ. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J Exp Med 1988;167:1767-79.
69. Foa R, Guarini A, Gansbacher B. IL2 treatment for cancer: from biology to gene therapy. Br J Cancer 1992;66:992-8.
70. Driscoll J, Brown MG, Finley D, Monaco JJ. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome [see comments]. Nature 1993;365:262-4.
71. Gaczynska M, Rock KL, Goldberg AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes [see comments] [published erratum appears in Nature 1995;374:290], Nature 1993;365:264-7.
72. Schumacher TN, Kantesaria DV, Heemels MT, et al. Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator. J Exp Med 1994;179:533-40.
73. Androlewicz MJ, Cresswell P. Human transporters associated with antigen processing possess a promiscuous peptide-binding site. Immunity 1994;1:7-14.
74. Momburg F, Roelse J, Howard JC, Butcher Gw, Hammerling GJ, Neefjes JJ. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 1994;367:648-51.
75. van Endert PM, Tampe R, Meyer TH, Tisch R, Bach JF, McDevitt HO. A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity 1994;1:491-500.
76. van Endert PM, Riganelli D, Greco G, et al. The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med 1995;182:1883-95.
77. Anderson K, Cresswell P, Gammon M, Hermes J, Williamson A, Zweerink H. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med 1991;174:489-92.
78. Davenport MP, Smith KJ, Barouch D, et al. HLA class I binding motifs derived from random peptide libraries differ at the COOH terminus from those of eluted peptides. J Exp Med 1997;185:367-71.
79. Peace-Brewer AL, Tussey LG, Matsui M, Li G, Quinn DG, Frelinger JA. A point mutation in HLA-A*0201 results in failure to bind the TAP complex and to present virus-derived peptides to CTL. Immunity 1996;4:505-14.
80. del Guercio MF, Sidney J, Hermanson G, et al. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 1995;154:685-93.
81. Lyons DS, Lieberman SA, Hampl J, et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 1996;5:53-61.
82. Valitutti S, Muller S, Celia M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes [see comments]. Nature 1995;375:148-51.
83. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds [see comments]. Science 1996;273:104-6.
84. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA. Shared human melanoma antigens: recognition by tumorinfiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 1992;148:638-43.
85. Zinkernagel RM, Pircher HP, Ohashi P, et al. T and B cell tolerance and responses to viral antigens in transgenic mice: implications for the pathogenesis of autoimmune versus immunopathological disease. Immunol Rev 1991;122:133-71.
86. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445-80.
87. Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992; 13:11-6.
88. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
89. Zinkernagel RM. Immunology taught by viruses [see comments]. Science 1996;271:173-8.
90. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72.
91. Seliger B, Maeurer MJ, Ferrone S. TAP off-tumors on. Immunol Today (in press).
92. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1 /CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
93. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma: tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 1995;21:128-51.
94. Luscher U, Filgueira L, Juretic A, et al. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer 1994;57:612-9.
95. Loftus DJ, Castelli C, Clay TM, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/ melanocyte-derived peptide MART-l(27-35). J Exp Med 1996;184:647-57.
96. Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones: identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989;170:797-810.
97. Crowley NJ, Darrow TL, Quinn-Alien MA, Seigler HF. MHC-restricted recongition of autologous melanoma by tumor-specific cytotoxic T cells: evidence for restriction by a dominant HLA-A allele. J Immunol 1991;146:1692-9.
98. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumorinfiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report [see comments], N Engl J Med 1988;319:1676-80.
99. Pellegrino MA, Ferrone S, Reisfeld RA, Irie RF, Golub SH. Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma. Cancer 1977;40:36-41.
100. Ruiter DJ, Mattijseen V, Broecker EB, Ferrone S. MHC antigens in human melanomas. Semin Cancer Biol 1991;2:35-45.
101. Natali PG, Nicotra MR, Bigotti A, et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 1989;86:6719-23.
102. Momburg F, Ziegler A, Harpprecht J, Moller P, Moldenhauer G, Hammerling GJ. Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J Immunol 1989;142:352-8.
103. Momburg F, Degener T, Bacchus E, Moldenhauer G, Hammerling GJ, Moller P. Loss of HLA-A, B, C and de novo expression of HLA-D in colorectal cancer. Int J Cancer 1986;37:179-84.
104. Holzmann B, Brocker EB, Lehmann JM, et al. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 1987;39:466-71.
105. D’Alessandro G, Zardawi I, Grace J, McCarthy WH, Hersey P. Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: relation to biology of melanoma. Pathology 1987;19:339-46.
106. Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M. Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991;51:6372-80.
107. Mechtersheimer G, Staudter M, Majdic O, Dorken B, Moldenhauer G, Moller P. Expression of HLA-A, B, C beta 2-microglobulin (beta 2m), HLA-DR, -DP, -DQ and of HLA-D-associated invariant chain (Ii) in soft-tissue tumors. Int J Cancer 1990;46:813-23.
108. Gattoni-Celli S, Kirsch K, Timpane R, Isselbacher KJ. Beta 2-microglobulin gene is mutated in a human colon cancer cell line (HCT) deficient in the expression of HLA class I antigens on the cell surface. Cancer Res 1992;52:1201-4.
109. D’Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expession. J Clin Invest 1991;87:284-92.
110. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA class I antigen expession by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Cin Invest 1993;91:684-92.
111. Ruiz-Cabello F, Perez-Ayala M, Gomez O, et al. Molecular analysis of MHC-class-I alterations in human tumor cell lines. Int J Cancer Suppl 1991;6:123-30.
112. Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG, Bodmer WF. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expession on colorectal tumor cell lines. Proc Natl Acad Sci USA 1993;90:2842-5.
113. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994;153:1225-37.
114. Marincola FM, Shamamian P, Simonis TB, et al. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol 1994;16:13-23.
115. Kageshita T, Wang Z, Calorini L, et al. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 1993;53:3349-54.
116. Rivoltini L, Baracchini KC, Viggiano V, et al. Quantitative correlation between HLA class I allele expession and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-57.
117. Dong-Chen S, Gammon MC, Zweerink HJ, Kao KJ. Functional significance of varied quantitative expression of HLA-A2.1 antigens in determining the susceptibility of cells to cytotoxic T lymphocytes. Hum Immunol 1996;46:18-26.
118. Skipper JC, Kittlesen DJ, Hendrickson RC, et al. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol 1996;157:5027-33.
119. Brichard VG, Herman J, Van Pel A, et al. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 1996;26:224-30.
120. Kang X, Kawakami Y, el-Gamil M, et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumorinfiltrating lymphocytes. J Immunol 1995;155:1343-8.
121. Visseren MJW, van Elsas A, van der Voort EIH, et al. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995;154:3991-8.
122. Morioka N, Kikumoto Y, Hoon DS, Morton DL, Irie Rf. A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 1994;153:5650-8.
123. van der Bruggen P, Szikora JP, Boel P, et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol 1994;24:2134-40.
124. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-30.
125. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-75.
126. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-98.
127. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996;183:1131-40.
128. Robbins PF, el-Gamil M, Li YF, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-50.
129. Salgaller ML, Weber JS, Koenig S, Yannelli JR, Rosenberg SA. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immnother 1994;39:105-16.